Cargando…

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects

Objective: Ertugliflozin is approved in the US and European Union as a stand-alone product for adults with type 2 diabetes mellitus as once daily (QD) dosing. The approved fixed-dose combination (FDC) of ertugliflozin and immediate-release metformin is dosed twice daily (BID). This study assessed st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dawra, Vikas Kumar, Liang, Yali, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Cutler, David, Sahasrabudhe, Vaishali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528385/ https://www.ncbi.nlm.nih.gov/pubmed/30802200 http://dx.doi.org/10.5414/CP203343

Ejemplares similares

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2018)

Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States
por: Dawra, Vikas Kumar, et al.
Publicado: (2020)

Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
por: Fediuk, Daryl J., et al.
Publicado: (2019)

Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial
por: Balk, Jiska M, et al.
Publicado: (2015)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects
por: Li, Yinhua, et al.
Publicado: (2019)

Compliance with Once-Daily versus Twice or Thrice-Daily Administration of Antibiotic Regimens: A Meta-Analysis of Randomized Controlled Trials
por: Falagas, Matthew E., et al.
Publicado: (2015)

Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease
por: Sakai, Yukinao, et al.
Publicado: (2013)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
por: Marshall, Jean‐Claude, et al.
Publicado: (2021)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
por: Woodcock, Ashley, et al.
Publicado: (2011)

Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
por: Yun, Ji Young, et al.
Publicado: (2013)

Effects of Converting Tacrolimus Formulation from Twice-Daily to Once-Daily in Liver Transplantation Recipients
por: Thorat, Ashok, et al.
Publicado: (2014)

Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety
por: Derington, Catherine G., et al.
Publicado: (2020)

Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation
por: Bzeizi, Khalid Ibrahim, et al.
Publicado: (2021)

A randomized trial of once daily versus twice daily dosing of oral iron in CKD
por: Sood, Vivek, et al.
Publicado: (2023)

Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2022)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure
por: Anand, Inder S, et al.
Publicado: (2010)

Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness
por: Baron, Jeffrey, et al.
Publicado: (2018)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial
por: Christodoulou, Marianna, et al.
Publicado: (2019)

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients
por: Ferhatoglu, Murat Ferhat, et al.
Publicado: (2021)

Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients
por: Hurwitz, Jason T, et al.
Publicado: (2021)

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Publicado: (2015)

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
por: Qaqish, R, et al.
Publicado: (2010)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?
por: Nachega, Jean B, et al.
Publicado: (2011)

Impact of Once-Daily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous Thromboembolism
por: Laliberté, François, et al.
Publicado: (2013)

The Effect of Orally Administered Ranitidine and Once‐Daily or Twice‐Daily Orally Administered Omeprazole on Intragastric pH in Cats
por: Šutalo, S., et al.
Publicado: (2015)

Once-daily vs. twice-daily dosing of enoxaparin for the management of venous thromboembolism: A systematic review and meta-analysis
por: Niu, Jingrong, et al.
Publicado: (2020)

Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies
por: Vadcharavivad, Somratai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1hc2imo983vfvvembvkvdn8dfv